Observational prospective cohort study on fluid infusion rate and cisplatin-associated complications
Art & Science Previous    

Observational prospective cohort study on fluid infusion rate and cisplatin-associated complications

Anita Zeneli Research nurse, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Oriana Nanni Director, biostatistic and clinical trials unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Elisa Carretta Biostatistician, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Lorenzo Cecconetto Oncologist, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Rosanna Tedaldi Head nurse, day hospital units of Forlì and Meldola, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Serena Maltoni Infusion nurse, meldola day hospital unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Ivana Barlati Director of nursing and technical service, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy
Dino Amadori Scientific director, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy

Anita Zeneli and colleagues present the results of research to investigate the links between chemotherapy duration time and events such as renal toxicity

Aim To evaluate the influence of hydration infusion rate on frequency of systemic complications during chemotherapy administration and intercycle follow up.

Method A prospective study of 101 adult cancer patients undergoing outpatient treatment was conducted. They received 145 cisplatin-based chemotherapy infusions. Cisplatin infusion rate was standard, while fluid infusion rate varied, according to chemotherapy schemas. Infusions were categorised using quartiles of the infusion times distributed into four categories.

Results Clinical response measured by renal output during infusion follow up was registered highest in the shortest duration category (P=0.0230). Anaemia during infusion and at intercycle follow up was associated with infusion duration (P=0.0007; P=0.0136). Renal and myelotoxicity were not statistically associated with infusion duration.

Conclusion The category of shortest infusion duration was the safest. Infusion times of fluid therapy may influence systemic complications during chemotherapy administration and intercycle follow up, and the risk of systemic events may increase in infusions lasting more than five hours. Infusion nurses should take this finding into consideration during care planning.

Cancer Nursing Practice. 12, 10,34-39. doi: 10.7748/cnp2013.12.12.10.34.e1026

Correspondence

a.zeneli@irst.emr.it

Peer review

This article has been subject to double blind peer review

Conflict of interest

None declared

Received: 09 September 2013

Accepted: 14 October 2013